Evogene Ltd.

Regulatory Filings • Apr 19, 2021

Biomica to Present at Jefferies Microbiome-Based Therapeutics Summit, on April 22nd, 2021

(Virtual Conference)

Rehovot, Israel – April 19, 2021 – Biomica Ltd., an emerging biopharmaceutical company developing innovative microbiome-based therapeutics, and a subsidiary of Evogene Ltd. (NASDAQ: EVGN, TASE: EVGN), today announced that Dr. Elran Haber, Chief Executive Officer of Biomica, will present at the Jefferies Microbiome-Based Therapeutics Summit being held on Thursday, April 22, 2021.

Dr. Haber will be available for one-on-one meetings during the summit.

A Pre-Recording of the Presentation will be made available on Thursday, April 22, 2021.

***

About Biomica:

Biomica is an emerging biopharmaceutical company developing innovative microbiome-based therapeutics utilizing a dedicated Computational Predictive Biology platform (CPB), licensed from Evogene. Biomica aims to identify and characterize disease-related microbiome entities and to develop novel therapeutics based on these understandings. The company is focused on the development of therapies for antibiotic resistant bacteria, immuno-oncology, and microbiome-related gastrointestinal (GI) disorders. Biomica is a subsidiary of Evogene Ltd. (NASDAQ: EVGN, TASE: EVGN). For more information, please visit www.biomicamed.com.

Contact:

Rivka Neufeld/ Aviva Banczewski Investor Relations and Public Relations Manager E: IR@evogene.com T: +972-8-931-1900

US Investor Relations: Joseph Green Edison Group E: jgreen@edisongroup.com T: +1 646-653-7030

Laine Yonker Edison Group E: lyonker@edisongroup.com T: +1 646-653-7035